ASCO GU 2015
ASCO GU 2015
Our collaborators are presenting three studies at the 2015 ASCO Genitourinary Cancers Symposium held in Orlando, Fla., that demonstrate how the Epic Sciences no cell left behind™ platform could be used as a blood test for certain types of metastatic prostate and bladder cancers — liquid biopsies to predict which patients will best respond to certain therapies before they are treated.
2015 ASCO GU POSTER PRESENTATIONS:
1. Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (Abstract 147)
Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)
Highlight: Selected for Audio Poster Tour
2. Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC. (Abstract 197)
Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)
3. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle-invasive (MIBC) and metastatic bladder cancer (mBCa) patients. (Abstract 353)
Friday 12:15 pm to 1:45pm and 6:00 pm to 7:00 pm (Poster Session B)